Consistent with the genetic depletion of EZH2, we observe a visible decrease of peritoneal metastasis following daily oral administration of EPZ6438 (250 mg/kg) though primary tumor burden remains the same in both the control and treatment group (Fig. 9N–P and Supplementary Fig. 4). This evidence concerns the gene EZH2 and neoplasm.